Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Britain Courts Anthropic Amid US Defense Department Dispute 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
CAMBRIDGE, Mass., July 31, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call in conjunction with the announcement of its second quarter 2017 financial results and present at the 2017 Wedbush PacGrow Healthcare Conference. Details of both events are as follows:
- Second Quarter 2017 Financial Results: Management will host a conference call and webcast at 8:00 a.m. ET on Friday, August 4, 2017, to discuss its second quarter 2017 financial results and other business highlights. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 48137127. The webcast can be accessed under "Events and Presentations" in the Investor Relations section of the company's website at www.epizyme.com.
- Wedbush PacGrow Healthcare Conference Presentation: Management will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 12:45 p.m. ET in New York City. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor Relations section of the company's website at www.epizyme.com.
Replays of both webcasts will be available in the investor section of the company’s website at http://www.epizyme.com for 60 days following the call and presentation.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting cancer treatment through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies as a monotherapy and combination therapy and in relapsed and front-line disease. Using the Company’s proprietary platform, Epizyme has pioneered the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, which can allow cancer cells to grow and proliferate. By focusing on the genetic drivers of cancers, Epizyme's science seeks to match targeted medicines with the specific patients that need it. For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.
Contacts: Cheya Pope, Epizyme, Inc. [email protected] 617-229-7561 Monique Allaire, THRUST IR [email protected] (617) 895-9511
